Press release
Myocardial Infarction Therapeutics Market Forecast By End-use Industry 2016-2026
Myocardial infarction, generally called as heart attack is characterized by reduced blood supply to the heart muscles, primarily due to coronary artery disease. According to American Heart Association (AHA), every year around 17.3 Mn people die of heart diseases worldwide, with myocardial infarction being the leading cause of death. In 2012, British Heart Foundation reported 73,680 deaths in United Kingdom due to coronary heart disease. Mortality from acute myocardial infarction can be decreased if patient receives the emergency access to the treatment. The global cardiovascular treatment market generated a revenue of 170 Bn in 2010 and is expected to expand drastically over the forecast period of 2016-2026. Multitude of products available for the treatment of acute myocardial infarction with different indications include Zorprin, Plavix, Angiomax, Diovan, Lovenox, Aggrastat, NitroStat, Benicar and many more.Myocardial Infarction Therapeutics Market: Drivers and Restraints
Increasing incidence of coronary artery disease and changes in lifestyle are the major factors expected to drive the growth of global myocardial infarction therapeutics market. Increasing number of smokers, increasing incidence of obesity and blood pressures, lack of exercise can be some other reasons likely to flourish the global myocardial infarction therapeutics market over the forecast period of 2016-2026. WHO findings show that the death rate due to cardiovascular diseases is more in smokers than that in non-smokers. Whereas, saturation in R&D can be the major restraint for the growth of global myocardial infarction therapeutics market.
Request to Sample Report - https://www.futuremarketinsights.com/reports/sample/rep-gb-1263
Myocardial Infarction Therapeutics Market: Segmentation
The global myocardial infarction therapeutics market has been classified on the basis product type, distribution channel and geography.
Based on product type, the global myocardial infarction therapeutics market is divided into following:
Analgesics
Antiplatelet agents
Vasodilators
Thrombolytics and anti-thrombotic agents
Glycoprotein IIb/IIIa inhibitors
Î’ adrenergic blockers
Angiotensin receptor antagonists
Angiotensin converting enzyme inhibitors
Based on distribution channel, the global blood canner treatment market is divided into following:
Hospitals
Hospital Pharmacies
Drug Stores
Online drug stores
Myocardial Infarction Therapeutics Market: Overview
Analgesics and antiplatelet agents’ segments are foreseen to hold more share in global myocardial infarction therapeutics market as these agents are used for initial treatment of an acute myocardial infarction. Amongst sales channels, hospital pharmacy segment is expected to contribute more into global myocardial infarction therapeutics market. The global myocardial infarction therapeutics market is foreseen to experience the boost in market volume over the forecast period due to the launch of several new products such as Apixaban, Xarelto and introduction of generic drugs after expiration of patents for Crestor and Benicar.
Request Report TOC @ https://www.futuremarketinsights.com/toc/rep-gb-1263
Myocardial Infarction Therapeutics Market: Regional Overview
Geographically, the global myocardial infarction terapeutic market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America will continue to take leading position in global myocardial infarction therapeutic market owing to expanding aging population and prevalence of co-morbidities. The expiry of blockbuster drugs in European market is likely to deter the segment share in global myocardial infarction therapeutics market. Japan is expected to experience the stagnancy in global myocardial infarction therapeutics market, in part due to saturation in R&D.
Myocardial Infarction Therapeutics Market: Key Players
Some of the key players in global myocardial infarction therapeutics market are Novartis N.V., Daiichi Sankyo Company Limited, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, AstraZeneca, Apotex Inc., Sandoz, Par Pharmaceutical Companies, Inc., Mylan N.V., Pfizer Inc.
ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website :www.futuremarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myocardial Infarction Therapeutics Market Forecast By End-use Industry 2016-2026 here
News-ID: 951535 • Views: …
More Releases from Future Market Insights

Fiber Supplements Market Projected to Reach USD 41.3 Billion by 2035, Driven by …
The global fiber supplements market is set to witness strong expansion over the next decade. Valued at USD 22.0 billion in 2025, the market is projected to reach USD 41.3 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.5%. The surge in demand is being driven by increasing consumer awareness of digestive health, cardiovascular well-being, and lifestyle-related disease prevention.
Gain Early Access to Market Insights - Request…

Global Food Grade Industrial Gases Market Poised to Surpass USD 12.5 Billion by …
A new market analysis reveals that the global Food Grade Industrial Gases Market is on a robust growth trajectory, with its value projected to rise from an estimated USD 8.5 billion in 2025 to USD 12.6 billion by 2035, marking a steady Compound Annual Growth Rate (CAGR) of 4.0% over the forecast period. The findings highlight a market propelled by escalating consumer demand for fresh, convenient, and safe food products,…

Food Texturing Agents Market to Reach USD 19.9 Billion by 2035 Amid Rising Deman …
The Food Texturing Agents Market is set for steady expansion, with its valuation projected at USD 13.4 billion in 2025 and anticipated to reach USD 19.9 billion by 2035, advancing at a compound annual growth rate (CAGR) of 4.0%.
This growth is attributed to the increasing demand for processed, convenience, and plant-based foods as consumers place greater emphasis on taste, mouthfeel, shelf life, and product consistency. Food texturing agents-ranging from emulsifiers…

Savory Ingredient Market Set to Reach USD 15.9 Billion by 2035, Driven by Rising …
The Savory Ingredient Market is projected to grow steadily, rising from USD 10.3 billion in 2025 to USD 15.9 billion by 2035, registering a compound annual growth rate (CAGR) of 4.4% during the forecast period. This growth is fueled by the increasing demand for bold and authentic flavors in processed foods, snacks, ready meals, and plant-based alternatives.
Stay Informed - Request a Sample Copy for Exclusive Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-915
Quick Stats for the…
More Releases for Myocardial
Driving Myocardial Infarction Market Growth in 2025: The Role of Increasing Numb …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Myocardial Infarction Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been a significant rise in the size of the myocardial infarction market. It is projected to expand from $2.05 billion in 2024 to $2.2 billion in 2025, exhibiting a compound annual…
Diabetes Epidemic Fuels Myocardial Ischemia Market Growth: An Emerging Driver Tr …
The Myocardial Ischemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Myocardial Ischemia Market?
The myocardial ischemia market has grown strongly. It will grow from $0.79 billion in 2024 to $0.85 billion in 2025 at a CAGR of 7.3%.…
Transforming the Myocardial Ischemia Market in 2025: Diabetes Epidemic Fuels Myo …
What Is the Expected Size and Growth Rate of the Myocardial Ischemia Market?
The market size for myocardial ischemia has demonstrated considerable growth over the last few years. There's a predicted growth from $0.79 billion in 2024 to $0.85 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial growth during the historical period can be credited to the use of telemedicine and remote monitoring, the discovery…
Myocardial Infarction Treatment Market Growth and Insights 2024
"The Business Research Company recently released a comprehensive report on the Global Myocardial Infarction Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Myocardial Infarction Drugs Market
According to a new report published by Allied Market Research, titled, "Myocardial Infarction Drugs Market by Product Type (Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics, Anti-Thrombotic Agents, Glycoprotein IIb/IIIa Inhibitors, Î' Adrenergic Blockers, Angiotensin Receptor Blockers, and Angiotensin Converting Enzyme Inhibitors) and by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, and Online Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2019-2026".
The Global market size of Myocardial Infarction Drugs Market was $XX…
Myocardial Ischemia - Pipeline Review, H1 2017 - Pharmaceutical Report
Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm…